Why Is LEMAITRE VASCULAR IN (LMAT) Stock Down Today?
By the Top Tier Newswire AI Desk · August 5, 2026 at 9:36 AM ET · reviewed against 5 wire stories
LEMAITRE VASCULAR IN (LMAT) is down -15.28% in the latest session. Our newswire has captured 5 stories on LMAT across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why LMAT stock is down today
LeMaitre Vascular stock fell 15.28% to $89.62 in early trading on August 5, 2026. The decline followed the company’s Q2 2026 earnings report, which revealed earnings and revenue that fell short of estimates. The stock opened with a 12.1% gap down from the prior close and continued to decline through the session. The move reflects investor reaction to the company’s reduced guidance and supply chain challenges.
What Happened
LeMaitre Vascular reported Q2 2026 results that included GAAP earnings per share of $0.74, below the $0.79 estimate. Revenue came in at $70.382 million, missing the $70.973 million forecast. The company cited FX pressures, export delays, and supply risks as factors behind the underperformance. In response, LeMaitre lowered its full-year 2026 guidance. The company reduced GAAP EPS guidance from $2.93, $3.08 to $2.84, $2.94 and cut revenue guidance from $277.000 million, $283.000 million to $274.300 million, $278.300 million. The Artegraft product line, which now accounts for 21% of revenue, continues to drive growth, but the near-term challenges have dampened investor sentiment.
What The Data Shows
The stock opened at $93.00, a 12.1% gap down from the previous close of $105.78. It reached a session low of $85.85 before closing the session at $89.62. The volume of 0.1 million shares was 0.3 times the 3-month average. LeMaitre has a market cap of $2.4 billion and a P/E ratio of 38.9. The company’s trailing twelve-month revenue grew by 13.3%, and its net margin stands at 24.3%. Recent insider transactions include four sales totaling $6.3 million over the past 90 days, with the most recent filing on May 11, 2026.
What To Watch
LeMaitre Vascular is scheduled to release its Q3 2026 earnings report in the coming months. Investors will be watching for further clarity on the company’s ability to navigate supply chain issues and execute on its Artegraft expansion. Coverage of the stock remains active, with five stories published in the last 36 hours.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
LMAT · Aug 5 session (5-min) · -24.01% vs prior close · updated 8:57 PM ETAI sentiment, last 36h · averaged over 5 stories · 57/100 bullish
The headlines behind the move
Story flow · 5 stories on the wire, last 36h · hover or tap a dot for the headline
5d agoMarketChameleonBULLISH 73Earnings
Artegraft Drives Record Growth as LeMaitre Delivers Strong Margins and Expands Global Reach
August 5, 2026
LeMaitre Vascular’s Q2 2026 results underscore the impact of its Artegraft roll-out, which now represents 21% of revenue. With broad-based product and geographic growth, improved margins, and a robust outlook, LeMaitre demonstrates financial strength and strategic flexibility.
5d agoSeeking AlphaBULLISH 56Earnings
LeMaitre projects $276.3M 2026 revenue amid 11% organic growth outlook and Artegraft expansion
Filed: 2026-08-04 AccNo: 0001193125-26-332982 Size: 383 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
6d agoBusiness InsiderBULLISH 56Earnings
LeMaitre Q2 2026 Financial Results
BURLINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →